Eosinophilic Esophagitis: Choosing Among Three Real First-Line Options
Three legitimate first-line options for newly diagnosed EoE — a PPI trial, swallowed topical steroid, and the six-food elimination diet — carry genuinely comparable efficacy, which makes this less a clinical-evidence question and more a question of what this particular patient can actually sustain.
Renata S., 34, lives alone in a small apartment above the bakery where she's worked mornings for six years, a schedule that has her eating most meals standing up between 5 and 9am before the counter opens. She came in after two years of slowly, quietly cutting foods out of her own diet — bread crusts, then bagels entirely, then most sandwiches — without ever naming it as a symptom to anyone until a coworker asked why she'd stopped eating the day-old rolls she used to take home. Endoscopy showed the ringed, furrowed esophagus typical of EoE; biopsies confirmed 38 eosinophils/hpf. She has no other GI history and no known food allergies, though she has never been formally tested.
All three standard first-line options — an 8-week PPI trial, swallowed topical budesonide, and the six-food elimination diet — carry broadly comparable rates of histologic remission, so this isn't a case where the evidence itself picks a winner. The comparison is largely indirect: each has been tested chiefly against placebo, and the 2025 ACG guideline (Dellon and colleagues) accordingly recommends choosing among them by shared decision-making rather than ranking them. What actually differs is what each option asks of her daily life: SFED requires eliminating milk, wheat, egg, soy, nuts, and seafood/shellfish simultaneously, with a structured, staged reintroduction process across repeat endoscopies to identify the real trigger; that's a heavier logistical ask for someone whose whole working day already happens in a bakery kitchen than it would be for someone with more control over what's around them.
No head-to-head trial has ranked the three against each other at 8-12 weeks, and the indirect comparisons that exist separate none of them cleanly — which is what makes a shared decision the correct clinical move here rather than a courtesy. Renata's own words, once the options were laid out plainly rather than ranked by convention, were that she'd rather try the thing she could actually keep up while standing at a bakery counter than the one a guideline happened to list first.
Three roughly equal options, one real life to fit them into
All three options put her in roughly the same place on histologic remission in the trials that have compared them head to head. Given that, I don't think the deciding factor should be which one we're most used to prescribing — it should be which one she can actually live with. She works a 5am bakery shift; SFED's staged reintroduction alone means at least three or four additional endoscopies over the next year to identify her trigger, on top of restricting six food categories at once starting immediately.
I don't disagree that it's a heavier lift, and I wouldn't push her toward it. But I want to be clear about what SFED actually offers that the other two don't: a real chance to identify her specific trigger food and come off restriction, or off medication, entirely once it's found. That's not just a third equivalent option — it's the only one with a possible exit.
It's fair to name the logistical cost honestly rather than undersell it to make the option look more attractive than it is for her specific situation.
You've framed it as the heaviest lift of the three, and I won't dispute the logistics — but I don't think "harder to arrange" should be read as "less worth naming" for a patient who might specifically want the one option that doesn't mean daily medication indefinitely.
One thing worth putting on the table plainly: she has no reflux symptoms. A PPI trial would still be reasonable — EoE response to PPI isn't actually about acid suppression the way GERD is, current understanding is that PPIs also have a direct anti-inflammatory, IL-13-related effect on esophageal epithelium independent of pH — but it does mean daily acid suppression she doesn't otherwise need, for as long as she stays on it. That's not a reason to rule it out. It's a reason to make sure she's choosing it for the right reason, not because it sounds like the easiest option.
Agreed, and genuinely her own decision once all three were explained without steering: an 8-week PPI trial first, with repeat endoscopy and biopsy at the end to confirm histologic response rather than just symptom relief.
Not closed, by design: she asked to revisit SFED specifically if the PPI trial fails or if her schedule changes — noted directly in the plan rather than left as an assumption either she or the team would have to re-raise from scratch later.